Search

for
Search:

Glossary Clascoterone

topical medication that blocks androgen receptors to treat hair loss

Clascoterone is a topical medication used to treat acne and androgenetic alopecia (a common form of hair loss). It works by blocking androgen receptors in the skin, which helps reduce the effects of hormones like testosterone that can contribute to these conditions.

Related Terms

Winlevi

Learn

1 / 2 results

learn Clascoterone

Topical androgen-receptor blocker, approved as an acne cream

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.
Does clascoterone have any side effects? Most reported side effects of clascoterone are skin irritation, but the acne-cream label also warns of stress-hormone (HPA-axis) suppression and raised potassium in some patients.
Can I use clascoterone if I'm undergoing gender-affirming hormone therapy? No published clinical trial has tested clascoterone in people on gender-affirming hormone therapy, so its safety in that group is unknown. The FDA label reports low systemic exposure and no described effect on blood testosterone, but it also records HPA-axis suppression and raised potassium in a small minority of subjects.

View more "clascoterone" in learn →

Research

5 / 112 results

research Clascoterone: First Approval

27 citations , October 2020 in “Drugs”

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

research Use of topical clascoterone for the treatment of hidradenitis suppurativa

10 citations , April 2023 in “JAAD Case Reports”

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist

9 citations , April 2021 in “Expert opinion on pharmacotherapy”

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

research Clascoterone as a novel treatment for androgenetic alopecia

5 citations , May 2020 in “Clinical and Experimental Dermatology”

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist

5 citations , December 2011 in “Drug Research”

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

View more "clascoterone" in research →

Community Join

5 / 246 results

community Clascoterone Phase 3 Results and Efficacy

10 upvotes 1 week ago

Clascoterone showed a 2.39x improvement over 12 months, but users are skeptical due to lack of detailed data like actual hair count increase. The conversation questions the efficacy compared to existing treatments like Minoxidil and Finasteride.

community Why isn’t Clascoterone being discussed more?

5 upvotes 2 weeks ago

Clascoterone is seen as a promising alternative for those who can't tolerate finasteride due to side effects like reduced libido and anxiety. Users discuss using topical finasteride and minoxidil for hair maintenance and consider Clascoterone as a potential future treatment.

community Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)

4 upvotes 4 weeks ago

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

community Clascoterone full results 2026

7 upvotes 1 month ago

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

community Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?

46 upvotes 1 month ago

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

View more "clascoterone" in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →